New York: Researchers have discovered a protein that may slow the spread of the human immunodeficiency virus (HIV), thereby revealing a target for developing natural therapies against the deadly virus.
“In earlier studies, we knew that we could interfere with the spread of HIV-1, but we couldn’t identify the mechanism that was stopping the process,” said study co-author Yong-Hui Zheng, associate professor of microbiology and molecular genetics at Michigan State University in the US.
The researchers found that the protein ERManI prevents the HIV virus from replicating.
“We now know that ERManI is an essential key, and that it has the potential as a antiretroviral treatment,” Zheng noted.
Currently, there is no cure for HIV-1. Once patients have it, they have it for life. While there are antiretroviral therapies available, they can only prolong life, albeit dramatically, but they cannot cure the disease.
Current drug treatments have to be taken for a lifetime, which causes side effects and many other issues, Zheng said.
“We see a way to treat this disease by helping the body protect itself,” he noted.
While it could be decades before an ERManI-based treatment can be prescribed for HIV-1 patients, these results provide a strong path for future research involving human cells, and later, clinical tests.
The next steps will be to test if HIV resistance can be promoted by increasing ERManI levels, Zheng pointed out.
The findings were detailed in the Journal of Biological Chemistry.
Thirty-six million people currently live with AIDS, a disease that claimed the lives of nearly 1 million people last year. Experts predict that by 2030, 100 million people will have been infected with the HIV virus.
Despite the alarming numbers, there have been great strides in treatment. HIV is no longer a death sentence, and researchers say people receiving treatment for HIV are able to live normal lives and do not pose a risk to others when they are being treated proactively.
But success carries a price: complacency. Funding for AIDS research and treatment has declined, and in some places, so has government interest.
“When we talk to ministers of finance, they always say to me, ‘I thought HIV was over because I don’t see anybody dying,’” said Dr. Deborah Birx, a U.S. Global AIDS coordinator who oversees the President’s Emergency Plan for AIDS Relief (PEPFAR).
J. Stephen Morrison of the Center for Strategic and International Studies, said, “We’re not reaching goals.” He added, “There’s going to be a struggle to hold ground. … There’s a widening deficit of political will and financial capacity that we face some really daunting challenges in prevention.”
Dr. Chris Beyrer, with Johns Hopkins Medicine, predicted that things will get worse if governments and civilians continue their complacency.
“We are not done with AIDS,” he said. “It is much too early to declare victory, and the risks of a resurgent epidemic are real.”
Birx, Morrison and Beyrer discussed the challenges in ending AIDS at a program in Washington to evaluate the messages from this year’s International AIDS Conference in Amsterdam.
New infections are down from 3.4 million a year, but they’re stuck at 1.8 million per year. And there are 17 million people living with HIV who cannot be reached. They are in high risk groups: young women, particularly young African women; men who have sex with men; IV drug users; those in prisons and other closed settings; sex workers and their clients; and transgender people.
“Those key populations and young women account for over 50 percent of new infections, and they are really hard to reach,” Morrison said.
Watch the video for more:
Though it’s relatively easy to prevent HIV transmission during childbirth, Beyrer said about 30 percent of all infants born with HIV worldwide are born in Nigeria.
In the U.S., HIV is increasingly an infection in communities with high rates of poverty and in black and Hispanic populations.
The National Institutes of Health announced Aug. 20 that getting these groups into care is critical to ending the HIV epidemic in the U.S. NIH also announced an international program to reduce the stigma around the virus so more people with the disease can seek treatment.
Experts agree it is possible to end the HIV pandemic, even without a vaccine. But to do this, governments and communities need to be involved, funding needs to be continued, and everyone with HIV needs to be treated. (VOA)